BioCentury | Feb 26, 2020
Distillery Therapeutics

Boosting FGF21 signaling to treat pancreatitis

DISEASE CATEGORY: Gastrointestinal INDICATION: Pancreatitis FGF21 replacement therapy or inhibition of PERK-mediated FGF21 repression could treat pancreatitis. Pancreatic levels of FGF21 protein were lower in 52 patients with acute or chronic pancreatitis than in 14...
BioCentury | Dec 19, 2019

Targeting the integrated stress response to treat Down syndrome

...ISR) by activating EIF2B or inhibiting EIF2AK2 could treat Down syndrome. Levels of phosphorylation of EIF2AK2...
...other ISR modulators for cognitive decline. TARGET/MARKER/PATHWAY: Eukaryotic translation initiation factor 2 α kinase 2 (EIF2AK2...
...San Francisco, Calif. email: peter@walterlab.ucsf.edu Claire Quang Calico Life Sciences LLC Baylor College of Medicine University of California San Francisco Eukaryotic translation initiation factor 2 alpha kinase 2 (EIF2AK2) Eukaryotic...
BioCentury | Jul 8, 2019
Financial News

On heels of series C extension, RAPT Therapeutics files for IPO

Just weeks after topping off its series C round, Flexus spinout RAPT Therapeutics Inc. (South San Francisco, Calif.) has filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill...
BioCentury | Mar 8, 2019
Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Otologic

INDICATION: Hearing loss Mouse studies suggest inhibiting DDIT3 or PERK could help treat hearing loss. In a mouse model of genetic hearing loss, systemic knockout of DDIT3 decreased hearing loss compared with normal DDIT3 expression....
BioCentury | Jul 19, 2018
Preclinical News

Inhibiting EIF2AK1 could help treat sickle cell disease

Researchers from Children’s Hospital of Philadelphia and University of Pennsylvania showed that inhibiting EIF2AK1 to increase fetal hemoglobin could help treat sickle cell disease. As genetic diseases such as SCD and some thalassemias affect patients...
BioCentury | Apr 10, 2018
Distillery Techniques

Drug delivery

...TECHNOLOGY: Nanoparticles Nanoparticles based on EIF2AK2 could be used to deliver siRNAs to treat cancer and...
...therapies in models of other diseases. DESCRIPTION: Eukaryotic translation initiation factor 2 α kinase 2 (EIF2AK2)-based...
...2, 2018 doi:10.1038/s41551-018-0214-1 CONTACT: Xiaohu Gao, University of Washington, Seattle, Wash. email: xgao@uw.edu Claire Quang University of Washington Eukaryotic translation initiation factor 2 alpha kinase 2 (EIF2AK2) Polo-like...
BioCentury | Feb 27, 2018
Emerging Company Profile

Stressing out cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells...
BioCentury | Feb 6, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Mouse studies suggest inhibiting PERK or IRE1 could help prevent embryonic microcephaly caused by Zika infection. In a mouse embryo model of Zika infection, tool compound PERK or IRE1 inhibitors decreased microcephaly...
BioCentury | Jun 22, 2017
Translation in Brief

TERS talk

A UCSD group has added "transmissible ER stress (TERS)" to the list of cancer's survival strategies. In a study published this month in Science Signaling , the group showed cancer cells undergoing ER stress send soluble...
Items per page:
1 - 10 of 31